CALL/EVOTEC/35/0.1/20.09.24 Stock

Warrant

DE000GQ56B22

Real-time BOERSE MUENCHEN 12:26:51 2024-06-20 EDT
0.011 EUR 0.00% Intraday chart for CALL/EVOTEC/35/0.1/20.09.24
Current month+22.22%
1 month-8.33%
Date Price Change
24-06-20 0.011 0.00%
24-06-19 0.011 -8.33%
24-06-18 0.012 0.00%
24-06-17 0.012 +9.09%
24-06-14 0.011 +22.22%

Real-time BOERSE MUENCHEN

Last update June 20, 2024 at 12:26 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying EVOTEC SE
Issuer Goldman Sachs
WKN GQ56B2
ISINDE000GQ56B22
Date issued 2023-09-20
Strike 35
Maturity 2024-09-20 (92 Days)
Parity 10 : 1
Emission price 0.05
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.071
Lowest since issue 0.007
Delta0.07x
Omega 3.934
Premium320.59x
Gearing59.68x
Moneyness 0.2387
Difference Strike 26.64
Difference Strike %+76.13%
Spread 0.01
Spread %52.63%
Theoretical value 0.0140
Implied Volatility 150.45 %
Total Loss Probability 98.82 %
Intrinsic value 0.000000
Present value 0.0140
Break even 35.14 €
Theta-0x
Vega0x
Rho0x

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
7.335 EUR
Average target price
20.79 EUR
Spread / Average Target
+183.44%
Consensus